ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder

BMC Urology

Volumn 11, Issue , 2011, Pages

  Shimada, Keiji ^a   Fujii, Tomomi ^a   Anai, Satoshi ^a   Fujimoto, Kiyohide ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DIPHENYLIODONIUM SALT; HYDROGEN PEROXIDE; PROTEIN P16; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; SUPEROXIDE; NOX4 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTODIAGNOSIS; DYSPLASIA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PAPANICOLAOU TEST; PRECANCER; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE CYTOLOGY; BLADDER TUMOR; CELL CULTURE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELLS, CULTURED; FEMALE; HUMANS; MALE; MIDDLE AGED; NADPH OXIDASE; REACTIVE OXYGEN SPECIES; URINARY BLADDER NEOPLASMS;

EID: 80054968168     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-11-22     Document Type: Article

References (30)

1. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Babjuk M, Oosterlinck W, Sylvester R, et al. European urology 2008 54 2 303 14 10.1016/j.eururo.2008.04.051 18468779
2. Development and progression of urothelial carcinoma. Kakizoe T, Cancer science 2006 97 9 821 8 10.1111/j.1349-7006.2006.00264.x 16822297 (Pubitemid 44151260)
3. Biomarkers in bladder cancer. Proctor I, Stoeber K, Williams GH, Histopathology 57 1 1 13
4. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Amin MB, Mod Pathol 2009 22 Suppl 2 96 S118 19494856
5. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Black PC, Brown GA, Dinney CP, Urologic oncology 2009 27 1 3 7 18367107
6. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Nigwekar P, Amin MB, Advances in anatomic pathology 2008 15 4 218 33 10.1097/PAP.0b013e31817d79b9 18580098
7. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. Black PC, Brown GA, Dinney CP, J Clin Oncol 2006 24 35 5528 35 10.1200/JCO.2006.08.0895 17158538 (Pubitemid 46631333)
8. Biomarkers for detection and surveillance of bladder cancer. Budman LI, Kassouf W, Steinberg JR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2008 2 3 212 21
9. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T, Science (New York, NY 1995 270 5234 296 9 10.1126/science.270.5234.296
10. Activation of DNA synthesis and expression of the JE gene by catalase in mouse osteoblastic cells: possible involvement of hydrogen peroxide in negative growth regulation. Shibanuma M, Arata S, Murata M, Nose K, Experimental cell research 1995 218 1 132 6 10.1006/excr.1995.1139 7737353
11. Oxidative DNA damage causes mitochondrial genomic instability in Saccharomyces cerevisiae. Doudican NA, Song B, Shadel GS, Doetsch PW, Molecular and cellular biology 2005 25 12 5196 204 10.1128/MCB.25.12.5196-5204.2005 15923634 (Pubitemid 40781117)
12. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Irani K, Xia Y, Zweier JL, et al. Science (New York, NY 1997 275 5306 1649 52 10.1126/science.275.5306.1649 (Pubitemid 27120541)
13. The NADPH oxidase of phagocytic leukocytes. Segal AW, Shatwell KP, Annals of the New York Academy of Sciences 1997 832 215 22 10.1111/j.1749-6632.1997. tb46249.x 9704049 (Pubitemid 28045316)
14. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. Shimada K, Nakamura M, Anai S, et al. Cancer research 2009 69 7 3157 64 10.1158/0008-5472.CAN-08-3530 19293182
15. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Konishi N, Nakamura M, Kishi M, et al. The American journal of pathology 2002 160 4 1207 14 10.1016/S0002-9440(10)62547-3 11943705 (Pubitemid 34411624)
16. c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Shimada K, Nakamura M, Ishida E, et al. The American journal of pathology 2007 171 3 1003 12 10.2353/ajpath.2007. 070010 17690186 (Pubitemid 47440997)
17. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N, The Journal of pathology 2005 206 4 423 32 10.1002/path.1791 15906275 (Pubitemid 41025345)
18. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Shimada K, Nakamura M, De Velasco MA, et al. Cancer science 101 1 155 60
19. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Murata S, Iseki M, Kinjo M, et al. American journal of clinical pathology 134 6 862 72
20. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Mochizuki T, Furuta S, Mitsushita J, et al. Oncogene 2006 25 26 3699 707 10.1038/sj.onc.1209406 16532036 (Pubitemid 43980491)
21. Identification of clinically useful cancer prognostic factors: what are we missing? McShane LM, Altman DG, Sauerbrei W, Journal of the National Cancer Institute 2005 97 14 1023 5 10.1093/jnci/dji193 16030294 (Pubitemid 41417913)
22. Biomarkers in cancer staging, prognosis and treatment selection. Ludwig JA, Weinstein JN, Nature reviews 2005 5 11 845 56 10.1038/nrc1739 16239904 (Pubitemid 41746029)
23. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A, The Journal of urology 1999 162 1 53 7 10.1097/00005392-199907000-00014 10379739 (Pubitemid 29420879)
24. Urine markers for bladder cancer surveillance: a systematic review. van Rhijn BW, van der Poel HG, van der Kwast TH, European urology 2005 47 6 736 48 10.1016/j.eururo.2005.03.014 15925067 (Pubitemid 40745338)
25. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Grossman HB, Soloway M, Messing E, et al. Jama 2006 295 3 299 305 10.1001/jama.295.3.299 16418465 (Pubitemid 43112958)
26. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI, Reviews in urology 2008 10 2 120 35 18660854
27. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. Sarosdy MF, Schellhammer P, Bokinsky G, et al. The Journal of urology 2002 168 5 1950 4 10.1016/S0022-5347(05)64270-X 12394683
28. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. Halling KC, King W, Sokolova IA, et al. The Journal of urology 2002 167 5 2001 6 10.1016/S0022-5347(05)65072-0 11956427 (Pubitemid 34309646)
29. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Yoder BJ, Skacel M, Hedgepeth R, et al. American journal of clinical pathology 2007 127 2 295 301 10.1309/ADJL7E810U1H42BJ 17210520 (Pubitemid 46797189)
30. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Lokeshwar VB, Habuchi T, Grossman HB, et al. Urology 2005 66 6 Suppl 1 35 63 16399415 (Pubitemid 43049608)